149 related articles for article (PubMed ID: 35836883)
1. Stachydrine hydrochloride ameliorates cardiac hypertrophy through CaMKII/HDAC4/MEF2C signal pathway.
Li XQ; Lu S; Xia L; Shan XL; Zhao WX; Chen HH; Zhang C; Guo W; Xu M; Lu R; Zhao P
Am J Transl Res; 2022; 14(6):3840-3853. PubMed ID: 35836883
[TBL] [Abstract][Full Text] [Related]
2. Icariin inhibits hypertrophy by regulation of GPER1 and CaMKII/HDAC4/MEF2C signaling crosstalk in ovariectomized mice.
Zhao W; Shan X; Li X; Lu S; Xia L; Chen H; Zhang C; Guo W; Xu M; Lu R; Zhao P
Chem Biol Interact; 2023 Oct; 384():110728. PubMed ID: 37739049
[TBL] [Abstract][Full Text] [Related]
3. Stachydrine Hydrochloride Regulates the NOX2-ROS-Signaling Axis in Pressure-Overload-Induced Heart Failure.
Lu S; Liang Y; Yang S; Fu M; Shan X; Zhang C; Chen H; Zhao P; Lu R
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762672
[TBL] [Abstract][Full Text] [Related]
4. Stachydrine hydrochloride alleviates pressure overload-induced heart failure and calcium mishandling on mice.
Chen HH; Wang SN; Cao TT; Zheng JL; Tian J; Shan XL; Zhao P; Guo W; Xu M; Zhang C; Lu R
J Ethnopharmacol; 2020 Feb; 248():112306. PubMed ID: 31626909
[TBL] [Abstract][Full Text] [Related]
5. Stachydrine hydrochloride suppresses phenylephrine-induced pathological cardiac hypertrophy by inhibiting the calcineurin/nuclear factor of activated T-cell signalling pathway.
Zheng J; Tian J; Wang S; Hu P; Wu Q; Shan X; Zhao P; Zhang C; Guo W; Xu M; Chen H; Lu R
Eur J Pharmacol; 2020 Sep; 883():173386. PubMed ID: 32712088
[TBL] [Abstract][Full Text] [Related]
6. Stachydrine Ameliorates Cardiac Fibrosis Through Inhibition of Angiotensin II/Transformation Growth Factor β1 Fibrogenic Axis.
Liu X; Shan X; Chen H; Li Z; Zhao P; Zhang C; Guo W; Xu M; Lu R
Front Pharmacol; 2019; 10():538. PubMed ID: 31178725
[TBL] [Abstract][Full Text] [Related]
7. Targeting E3 Ubiquitin Ligase WWP1 Prevents Cardiac Hypertrophy Through Destabilizing DVL2 via Inhibition of K27-Linked Ubiquitination.
Zhao D; Zhong G; Li J; Pan J; Zhao Y; Song H; Sun W; Jin X; Li Y; Du R; Nie J; Liu T; Zheng J; Jia Y; Liu Z; Liu W; Yuan X; Liu Z; Song J; Kan G; Li Y; Liu C; Gao X; Xing W; Chang YZ; Li Y; Ling S
Circulation; 2021 Aug; 144(9):694-711. PubMed ID: 34139860
[TBL] [Abstract][Full Text] [Related]
8. Stachydrine ameliorates pressure overload-induced diastolic heart failure by suppressing myocardial fibrosis.
Chen HH; Zhao P; Zhao WX; Tian J; Guo W; Xu M; Zhang C; Lu R
Am J Transl Res; 2017; 9(9):4250-4260. PubMed ID: 28979698
[TBL] [Abstract][Full Text] [Related]
9. TRPA1 inhibition ameliorates pressure overload-induced cardiac hypertrophy and fibrosis in mice.
Wang Z; Xu Y; Wang M; Ye J; Liu J; Jiang H; Ye D; Wan J
EBioMedicine; 2018 Oct; 36():54-62. PubMed ID: 30297144
[TBL] [Abstract][Full Text] [Related]
10. Trans-cinnamaldehyde protects against phenylephrine-induced cardiomyocyte hypertrophy through the CaMKII/ERK pathway.
Qian D; Tian J; Wang S; Shan X; Zhao P; Chen H; Xu M; Guo W; Zhang C; Lu R
BMC Complement Med Ther; 2022 Apr; 22(1):115. PubMed ID: 35468773
[TBL] [Abstract][Full Text] [Related]
11. Ca
Duran J; Lagos D; Pavez M; Troncoso MF; Ramos S; Barrientos G; Ibarra C; Lavandero S; Estrada M
Front Pharmacol; 2017; 8():604. PubMed ID: 28955223
[TBL] [Abstract][Full Text] [Related]
12. Differential cardiac hypertrophy and signaling pathways in pressure versus volume overload.
You J; Wu J; Zhang Q; Ye Y; Wang S; Huang J; Liu H; Wang X; Zhang W; Bu L; Li J; Lin L; Ge J; Zou Y
Am J Physiol Heart Circ Physiol; 2018 Mar; 314(3):H552-H562. PubMed ID: 29196344
[TBL] [Abstract][Full Text] [Related]
13. Zerumbone prevents pressure overload-induced left ventricular systolic dysfunction by inhibiting cardiac hypertrophy and fibrosis.
Sari N; Katanasaka Y; Sugiyama Y; Sunagawa Y; Miyazaki Y; Funamoto M; Shimizu S; Shimizu K; Murakami A; Mori K; Wada H; Hasegawa K; Morimoto T
Phytomedicine; 2021 Nov; 92():153744. PubMed ID: 34563985
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of TUG1 rescues cardiomyocyte hypertrophy through targeting the miR-497/MEF2C axis.
Zhang G; Ni X
Open Life Sci; 2021; 16(1):242-251. PubMed ID: 33817315
[TBL] [Abstract][Full Text] [Related]
15. Stachydrine ameliorates isoproterenol-induced cardiac hypertrophy and fibrosis by suppressing inflammation and oxidative stress through inhibiting NF-κB and JAK/STAT signaling pathways in rats.
Zhao L; Wu D; Sang M; Xu Y; Liu Z; Wu Q
Int Immunopharmacol; 2017 Jul; 48():102-109. PubMed ID: 28499193
[TBL] [Abstract][Full Text] [Related]
16. Lercanidipine attenuates angiotensin II-induced cardiomyocyte hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4 signaling.
Chen Y; Yuan J; Jiang G; Zhu J; Zou Y; Lv Q
Mol Med Rep; 2017 Oct; 16(4):4545-4552. PubMed ID: 28849081
[TBL] [Abstract][Full Text] [Related]
17. Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice.
Lairez O; Cognet T; Schaak S; Calise D; Guilbeau-Frugier C; Parini A; Mialet-Perez J
J Neural Transm (Vienna); 2013 Jun; 120(6):927-35. PubMed ID: 23543114
[TBL] [Abstract][Full Text] [Related]
18. Peroxiredoxin-1 ameliorates pressure overload-induced cardiac hypertrophy and fibrosis.
Tang C; Yin G; Huang C; Wang H; Gao J; Luo J; Zhang Z; Wang J; Hong J; Chai X
Biomed Pharmacother; 2020 Sep; 129():110357. PubMed ID: 32531679
[TBL] [Abstract][Full Text] [Related]
19. Stachydrine Protects Against Pressure Overload-Induced Cardiac Hypertrophy by Suppressing Autophagy.
Cao TT; Chen HH; Dong Z; Xu YW; Zhao P; Guo W; Wei HC; Zhang C; Lu R
Cell Physiol Biochem; 2017; 42(1):103-114. PubMed ID: 28494450
[TBL] [Abstract][Full Text] [Related]
20. Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload.
Ago T; Yang Y; Zhai P; Sadoshima J
J Cardiovasc Transl Res; 2010 Aug; 3(4):304-13. PubMed ID: 20559781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
